TRACON to Report Second Quarter 2023 Financial Results and Provide Corporate Update on August 14, 2023
SAN DIEGO, Aug. 02, 2023 (GLOBE NEWSWIRE) — TRACON Pharmaceuticals, Inc. (Nasdaq:TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, announced today that it will report its second quarter 2023 financial and operating results after the close of U.S. financial markets on Monday, August 14, 2023. In addition, management will host a conference call to provide an update on corporate activities and discuss the financial results.
Related news for (TCON)
- TRACON Pharmaceuticals Announces Termination of ENVASARC Trial and Will Explore Strategic Alternatives Leveraging its In-House Product Development Platform
- TRACON Announces Publication in Clinical Cancer Research of Phase 2 Clinical Data for TRC102, a DNA Damage Repair Inhibitor, in Recurrent Glioblastoma Patients
- TRACON Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
- TRACON to Report First Quarter 2024 Financial Results and Provide Corporate Update on May 14, 2024
- TRACON Pharmaceuticals Announces Reverse Stock Split